NUCLIDIUM develops copper-based radiotheranostics for cancer diagnosis and treatment. It has closed a CHF 26 million Series B extension, bringing the round to CHF 105 million, to fund expanded phase 1/2 trials and production.
- Announced on
- Round
- Series B
- Amount
- CHF 26 M
- Location
- Basel, canton of Basel-Stadt
- Sector
- Biotech & life sciences
Investors
- Kurma Growth Opportunities Fund lead
- Angelini Ventures lead
- Aurea lead
- Wellington Partners lead
- Neva SGR lead
- DeepTech & Climate Fonds
- Bayern Kapital
- Vives Partners
- NRW.BANK
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic